Repair Biotechnologies

Repair Biotechnologies

Private
Syracuse, New YorkHealthcare & Life Scienceshttps://www.repairbiotechnologies.com

Last Round

Series A

Extension

Mar 26, 2024

Est. Valuation

$50M

Total Funding Raised

$24.76M

Company Overview

Repair Biotechnologies is a biotechnology company focused on developing therapies that target and reduce cholesterol levels, utilizing a safe and well-tolerated cholesterol-degrading platform to address medical conditions caused by excess cholesterol accumulation.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

atherosclerosis treatmentplaque reversalcholesterol degrading platformLNP-mRNA therapyintracellular cholesterolage-related diseaselongevity biotechmRNA therapyanti-aging biotechcardiovascular diseaselipid nanoparticle deliveryHomozygous Familial HypercholesterolemiaHoFHrare disease therapydrug discoverypreclinical biotechmetabolic dysfunction-associated steatohepatitisMASH

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Repair Biotechnologies Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Repair Biotechnologies Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionMar 26, 2024
Series AJun 16, 2023
SAFEMay 27, 2022
Pre SeedFeb 23, 2021
SeedSep 1, 2020
Seed
May 7, 2019

Key People

Founding team and executive leadership

Reason .

Chief Executive Officer

Executive Team

Repair Biotechnologies Investors

Notable investors and investment history

InvestorRounds
GrapeseedSAFE
BiovergeSAFE, Series A
Longevitytech.fundSAFE, Series A
VitaDAOSAFE
Thynk CapitalSAFE, Series A, Seed
Healthspan CapitalSAFE, Series A
SENS Research FoundationSAFE, Pre Seed, Series A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 19, 2025

    Developing novel mRNA therapy to stabilize atherosclerotic plaques.

  • Nov 19, 2025

    Partnering with AGC Biologics for novel mRNA therapy development.

Repair Biotechnologies Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Repair Biotechnologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Repair Biotechnologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersSyracuse, New York
Employee Range10
Year Founded2018
Last FundingMar 26, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.